IRONWOOD PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Liability
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Increase (Decrease) in Contract with Customer, Liability of -$875.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-02-16
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2019-12-31 was -$403.00K.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2020 was -$875.00K, a 200.00% decline from fiscal 2019.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2019 was $875.00K.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2016 was -$8.99M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$875.00K 10-K · filed 2023-02-16 | |||
| 2019-12-31 | -$403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $875.00K 10-K · filed 2022-02-18 | ||
| 2019-09-30 | $1.28M 10-Q · filed 2020-11-05 | |||
| 2018-09-30 | $13.52M 10-Q · filed 2019-10-31 | |||
| 2017-06-30 | $225.00K 10-Q · filed 2018-08-06 | |||
| 2016-12-31 | -$8.99M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |